(Source: MolMed SpA) PRESS RELEASE Long term assessment of TK clinical benefit presented at ASH Milan (Italy), 10 December 2012 - MolMed S.p.A. (MLM.MI) announces the presentation of the long term clinical benefit and safety data of its investigational cell-based therapy TK at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta (GA, U.S.). The overall analysis comprises 128 patients with high-risk haematological malignancies who were treated in different countries in 10 Phase I-II clinical trials with TK cells, i.e. genetically engineered donor T cells administered after haematopoietic stem cell transplants from healthy donors to improve the...
0 Responses to Long term assessment of TK clinical benefit presented at ASH (MolMed SpA)